Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial

2020 ◽  
Vol 7 (2) ◽  
pp. e122-e133 ◽  
Author(s):  
Andrew M Brunner ◽  
Traci M Blonquist ◽  
Daniel J DeAngelo ◽  
Malgorzata McMasters ◽  
Geoffrey Fell ◽  
...  
Keyword(s):  
High Risk ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Induction Chemotherapy ◽  
Phase 2 ◽  
Phase 2 Trial ◽  
Acute Myeloid

scholarly journals Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

2019 ◽  
Vol 6 (1) ◽  
pp. e29-e37 ◽  
Author(s):  
Nicholas J Short ◽  
Hagop M Kantarjian ◽  
Sanam Loghavi ◽  
Xuelin Huang ◽  
Wei Qiao ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Older Patients ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Phase 2 Trial ◽  
Acute Myeloid

Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study

2019 ◽  
Vol 6 (3) ◽  
pp. e122-e131 ◽  
Author(s):  
Noelle Frey ◽  
Jun Ho Jang ◽  
Jeff Szer ◽  
Árpád Illés ◽  
Hee-Je Kim ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Induction Chemotherapy ◽  
Phase 2 ◽  
Double Blind ◽  
Phase 2 Study ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document